Title |
Australian recommendations for EGFR T790M testing in advanced non–small cell lung cancer
|
---|---|
Published in |
Asia Pacific Journal of Clinical Oncology, July 2017
|
DOI | 10.1111/ajco.12699 |
Pubmed ID | |
Authors |
Thomas John, Jeffrey J Bowden, Stephen Clarke, Stephen B Fox, Kerryn Garrett, Keith Horwood, Christos S Karapetis |
Abstract |
First-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used as first-line therapy in patients with non-small cell lung cancer (NSCLC) harboring a sensitizing mutation in the EGFR gene. Unfortunately, resistance to these therapies often occurs within 10 months of commencing treatment and is mostly commonly due to the development of the EGFR T790M mutation. Treatment with the third-generation EGFR TKI, osimertinib can prolong progression free survival in patients with the T790M mutation, so it is important to determine the resistance mechanism in order to plan ongoing therapeutic strategies. Here we review the evidence and make recommendations for the timing of T790M mutation testing, the most appropriate specimens to test and the available testing methods in patients progressing during treatment with first line EGFR TKIs for NSCLC. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 40 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 13% |
Professor | 4 | 10% |
Student > Doctoral Student | 3 | 8% |
Student > Bachelor | 2 | 5% |
Professor > Associate Professor | 2 | 5% |
Other | 5 | 13% |
Unknown | 19 | 48% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 20% |
Biochemistry, Genetics and Molecular Biology | 4 | 10% |
Nursing and Health Professions | 3 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 8% |
Agricultural and Biological Sciences | 3 | 8% |
Other | 1 | 3% |
Unknown | 18 | 45% |